Arnica/Levisticum 6x comp. can alleviate musculoskeletal symptoms in breast cancer patients undergoing endocrine therapy: a case series

Breast cancer is the most common malignancy among women worldwide, and endocrine therapy (ET) is crucial for reducing recurrence and mortality in hormone receptor-positive cases. However, ET is often associated with adverse effects, especially musculoskeletal symptoms (MSS) such as arthralgia and myalgia, which impair daily functioning, decrease quality of life, and lead to early therapy discontinuation. Although some pharmacological and non-pharmacological options are available for managing ET-induced MSS, their effectiveness is limited, and so far, no general recommendations exist. In the context of integrative oncology, which combines conventional and complementary approaches, anthroposophic medicine has been proposed as a supportive strategy to address these challenges. This case series investigated the potential of the anthroposophic medicinal product Arnica/Levisticum 6x comp. for alleviating ET-induced MSS. Three patients with hormone receptor-positive breast cancer, all undergoing ET and experiencing significant MSS unresponsive to conventional management, were included. Clinical data were collected over at least three years of follow-up. The severity of musculoskeletal pain was evaluated using patient reporting and a visual analogue scale (VAS). All three patients reported marked and rapid improvement in ET-associated MSS after beginning treatment with Arnica/Levisticum 6x comp. Symptom relief was typically achieved within weeks, with an average reduction of 2-4 points on the VAS. Notably, symptom recurrence was observed during periods of medication interruption, and symptoms consistently resolved upon reintroduction of Arnica/Levisticum 6x comp., suggesting a beneficial therapeutic effect. Throughout the observation period, the medication was well tolerated, with no adverse effects reported. Patients experienced improvements in daily functioning and overall quality of life, which facilitated continued adherence to ET. This case series provides preliminary evidence for the effectiveness and safety of Arnica/Levisticum 6x comp. as a therapeutic option for managing ET-induced MSS in breast cancer patients. The sustained symptom relief, favorable tolerability, and long-term safety suggest that this anthroposophic medication may serve as a useful adjunct in supportive care, improving quality of life and promoting continued adherence to ET.